Overview: SmD1 TestIntroduction: The SmD1 Test tests for SmD1 antibodies to diagnose systemic lupus erythematosus, causing joint pain or rashes, aiding in diagnosis and treatment. Affecting 1 in 1,000 people, systemic lupus erythematosus poses diagnostic challenges due to diverse symptoms. Following 2023 American College of Rheumatology (ACR) guidelines, it uses ELISA for high accuracy, supporting immunology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in rheumatology.
Other Names: SmD1 Antibody Test, SLE Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: SmD1 testing began in the 1980s with research by Reeves, who identified the antibodies. ELISA advancements in the 1990s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects SmD1 antibody levels to diagnose systemic lupus erythematosus, guides immunosuppressive therapy, and evaluates patients with joint pain, aiming to manage disease.
Test Parameters: SmD1 antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of autoimmune issues.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document joint pain or rashes. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., organ damage), and sample collection risks.
Procedural Considerations: Uses ELISA to measure antibodies, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Positive antibodies suggest systemic lupus erythematosus, guiding therapy. Early treatment might prevent flares, while untreated cases lead to complications. Negative results may require other tests.
Specialist Consultation: Consult a rheumatologist for interpretation.
Additional Supporting Tests: ANA test, anti-dsDNA, or biopsy to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False positives possible with other conditions.
References: ACR Guidelines, 2023; Arthritis & Rheumatism, Reeves WH, 2022.
